Phaseline

Targets › GH1

GH1 (Somatotropin): drug programs, companies and trials

4 programs from 4 companies in 7 trials: 4 Phase 3, 3 Phase 2; Other, Metabolic and endocrine; next expected readout Dec 2026.

Plays an important role in growth control. Its major role in stimulating body growth is to stimulate the liver and other tissues to secrete IGF1. (UniProt, P01241)

Open in Phaseline: the race on GH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Xiamen Amoytop BiotechInpegsomatropin Injection
Pegylated recombinant human growth hormone (long-acting GH analog)
GH1Phase 3Small for Gestational Age; Turner Syndrome; Idiopathic Short Stature; Adult Growth Hormone DeficiencyDec 2027
Kexing BiopharmGB06
Recombinant human growth hormone (biosimilar)
GH1Phase 3Growth Hormone Deficiency (GHD)Jul 2028
Changchun GeneScience PharmaceuticalPEG-rhGH Injection (Jintrolong®)
Recombinant human growth hormone with polyethylene glycol modification for extended half-l
GH1Phase 2Short Stature Children Born Small for Gestational Age (SGA)Dec 2026
Intervene ImmuneTRIIM Treatment
Combination of somatropin (recombinant human growth hormone), metformin, and DHEA
GH1, AMPKPhase 2Epigenetic Aging–

Conditions

Growth Hormone Deficiency (GHD) (1) Small for Gestational Age (1) Turner Syndrome (1) Idiopathic Short Stature (1) Adult Growth Hormone Deficiency (1) Short Stature Children Born Small for Gestational Age (SGA) (1) Epigenetic Aging (1)

Modalities

small molecule (2), protein or peptide (1)

Companies

Kexing Biopharm (1) Xiamen Amoytop Biotech (1) Changchun GeneScience Pharmaceutical (1) Intervene Immune (1)

Related targets

AMPK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.